Go Pro
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free EVLO Stock Alerts

Evelo Biosciences (EVLO) Competitors

Evelo Biosciences logo
Compare

EVLO vs. GNCA, PXMD, GNCAQ, CMRA, and SYRS

Should you buy Evelo Biosciences stock or one of its competitors? MarketBeat compares Evelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evelo Biosciences include Genocea Biosciences (GNCA), PaxMedica (PXMD), Genocea Biosciences (GNCAQ), Comera Life Sciences (CMRA), and Syros Pharmaceuticals (SYRS). These companies are all part of the "pharmaceutical products" industry.

How does Evelo Biosciences compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Genocea Biosciences has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Evelo Biosciences Neutral

Evelo Biosciences' return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Evelo Biosciences N/A N/A N/A

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Genocea Biosciences has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Summary

Genocea Biosciences beats Evelo Biosciences on 5 of the 9 factors compared between the two stocks.

How does Evelo Biosciences compare to PaxMedica?

Evelo Biosciences (NASDAQ:EVLO) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Evelo Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Evelo Biosciences has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
PaxMedica Neutral

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 1.0% of PaxMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PaxMedica is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Summary

Evelo Biosciences beats PaxMedica on 5 of the 8 factors compared between the two stocks.

How does Evelo Biosciences compare to Genocea Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A
Genocea BiosciencesN/AN/AN/AN/AN/A

Evelo Biosciences has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Genocea Biosciences has a beta of 2.44, suggesting that its share price is 144% more volatile than the broader market.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Genocea Biosciences Neutral

0.3% of Evelo Biosciences shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Genocea Biosciences N/A N/A N/A

Summary

Evelo Biosciences and Genocea Biosciences tied by winning 2 of the 4 factors compared between the two stocks.

How does Evelo Biosciences compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

0.3% of Evelo Biosciences shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by insiders. Comparatively, 1.0% of Evelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Evelo Biosciences Neutral

Comera Life Sciences has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Evelo Biosciences N/A N/A N/A

Summary

Comera Life Sciences beats Evelo Biosciences on 4 of the 7 factors compared between the two stocks.

How does Evelo Biosciences compare to Syros Pharmaceuticals?

Syros Pharmaceuticals (NASDAQ:SYRS) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Evelo Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Evelo Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$386K0.01-$164.57M-$3.03N/A
Evelo BiosciencesN/AN/A-$114.53M-$8.81N/A

Syros Pharmaceuticals has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.3% of Evelo Biosciences shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Syros Pharmaceuticals Neutral
Evelo Biosciences Neutral

Evelo Biosciences' return on equity of 0.00% beat Syros Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Syros PharmaceuticalsN/A -3,369.56% -97.04%
Evelo Biosciences N/A N/A N/A

Summary

Evelo Biosciences beats Syros Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Get Evelo Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EVLO vs. The Competition

Export
MetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$2K$791.45M$7.16B$12.48B
Dividend YieldN/A4.84%2.66%6.52%
P/E Ratio0.001.6628.0224.70
Price / SalesN/A127.11540.3799.49
Price / CashN/A20.0649.2657.09
Price / BookN/A8.1710.966.46
Net Income-$114.53M-$3.71M$3.57B$337.01M

Evelo Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120
GNCA
Genocea Biosciences
N/AN/AN/AN/A$6K$1.91MN/A70
PXMD
PaxMedica
N/A$0.00
flat		N/AN/A$6KN/AN/A2
GNCAQ
Genocea Biosciences
N/AN/AN/AN/A$5KN/AN/A70
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:EVLO) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel